These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 38673787)

  • 1. Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
    Ionita-Radu F; Patoni C; Nancoff AS; Marin FS; Gaman L; Bucurica A; Socol C; Jinga M; Dutu M; Bucurica S
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease.
    Zhu X; Bian H; Gao X
    Molecules; 2016 Oct; 21(10):. PubMed ID: 27754444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
    Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds.
    Ragab SM; Abd Elghaffar SKh; El-Metwally TH; Badr G; Mahmoud MH; Omar HM
    Lipids Health Dis; 2015 Jul; 14():83. PubMed ID: 26228038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
    Zhang YP; Deng YJ; Tang KR; Chen RS; Liang S; Liang YJ; Han L; Jin L; Liang ZE; Chen YN; Yang QH
    Curr Med Sci; 2019 Feb; 39(1):37-43. PubMed ID: 30868489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.
    Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K
    Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
    Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
    Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
    Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH.
    Cervello M; Augello G; Cocco L; Ratti S; Follo MY; Martelli AM; Cusimano A; Montalto G; McCubrey JA
    Adv Biol Regul; 2024 May; 92():101032. PubMed ID: 38693042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats.
    Zhong M; Yan Y; Yuan H; A R; Xu G; Cai F; Yang Y; Wang Y; Zhang W
    Food Funct; 2022 Jul; 13(13):7287-7301. PubMed ID: 35726797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Berberine in Non-Alcoholic Fatty Liver Disease-A Review.
    Koperska A; Wesołek A; Moszak M; Szulińska M
    Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
    Kimura T; Singh S; Tanaka N; Umemura T
    Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.
    Lu Z; Lu F; Wu L; He B; Chen Z; Yan M
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):383-390. PubMed ID: 32524150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).
    Grattagliano I; Di Ciaula A; Baj J; Molina-Molina E; Shanmugam H; Garruti G; Wang DQ; Portincasa P
    Methods Mol Biol; 2021; 2310():201-246. PubMed ID: 34096005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease.
    Lakhani HV; Sharma D; Dodrill MW; Nawab A; Sharma N; Cottrill CL; Shapiro JI; Sodhi K
    Int J Med Sci; 2018; 15(14):1591-1599. PubMed ID: 30588181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
    Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
    Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.